Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Remote ischemic conditioning wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Baker Heart and Diabetes Institute wikipedia , lookup
Myocardial infarction wikipedia , lookup
History of invasive and interventional cardiology wikipedia , lookup
Coronary artery disease wikipedia , lookup
Online Appendix for the following October 18 JACC article TITLE: Evolution in Cardiovascular Care for Elderly Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE National Quality Improvement Initiative AUTHORS: Karen P. Alexander, MD, Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina, Matthew T. Roe, MD, Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina, Anita Y. Chen, MS, Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina, Barbara L. Lytle, MS, Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina, Charles V. Pollack, Jr., MD, MA, Pennsylvania Hospital, Philadelphia, Pennsylvania, Joanne M. Foody, MD, Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, William E. Boden, MD, Division of Cardiology, Hartford Hospital, Hartford, Connecticut, Sidney C. Smith, Jr., MD, Department of Cardiology, University of North Carolina, Chapel Hill, North Carolina, W. Brian Gibler, MD, Department of Emergency Medicine, University of Cincinnati School of Medicine, Cincinnati, Ohio, E. Magnus Ohman, MD, Department of Cardiology, University of North Carolina, Chapel Hill, North Carolina, Eric D. Peterson, MD, MPH, Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina, for the CRUSDADE Investigators APPENDIX Hospital Care Anti-Ischemic Therapy IB: Beta-blocker, with the first dose intravenously if ongoing chest pain, in the absence of contraindications. IB: Non-dihydropyridine calcium antagonist (e.g., verapamil or diltiazem), in patients with continuing or recurring ischemia when beta-blockers are contraindicated, in the absence of severe left ventricular dysfunction. IB: Angiotensin-converting enzyme inhibitor when hypertension persists despite treatment with nitroglycerine and a beta-blocker in patients with left ventricular systolic dysfunction or congestive heart failure and in acute coronary syndrome patients with diabetes. Antiplatelet and Anticoagulation Therapy IA: Antiplatelet therapy should be initiated promptly. Aspirin should be administered as soon as possible after presentation and continued indefinitely. Clopidogrel should be administered to patients unable to take aspirin. IA: In patients in whom an early conservative approach is planned, clopidogrel should be added to aspirin as soon as possible on admission and administered for at least one month, and for up to nine months. IA: In patients for whom a percutaneous coronary intervention is planned and who are not at high risk for bleeding, clopidogrel should be started and continued for at least one month and for up to nine months. IA: Glycoprotein IIb/IIIa antagonist should be administered, in addition to aspirin and heparin, to patients in whom catheterization and percutaneous coronary intervention are planned. The glycoprotein IIb/IIIa antagonist may be administered prior to percutaneous coronary intervention. IA: Anticoagulation with subcutaneous low-molecular-weight heparin or intravenous unfractionated heparin should be added to antiplatelet therapy with aspirin and/or clopidogrel. Early Conservative Versus Invasive Strategies IA: An early invasive strategy in patients with unstable angina/non–ST-segment myocardial infarction without serious comorbidity with high-risk indicators: (a) recurrent angina/ischemia at rest or with low-level activities despite intensive anti-ischemic therapy; (b) elevated TnT or TnI; (c) new or presumably new ST-segment depression; (d) recurrent angina/ischemia with congestive heart failure symptoms, an S3 gallop, pulmonary edema, worsening rales, or new or worsening mitral regurgitation; (e) high-risk findings on noninvasive stress testing; (f) depressed left ventricular systolic function (e.g., ejection fraction <0.40 on noninvasive study); (g) hemodynamic instability; (h) sustained ventricular tachycardia; (i) percutaneous coronary intervention within six months; (j) or prior coronary artery bypass grafting. IB: In the absence these findings, either early conservative or early invasive strategy may be considered. Discharge and Post-Hospital Care IA: Aspirin 75 to 325 mg/day in the absence of contraindications. IA: Angiotensin-converting enzyme inhibitors for patients with congestive heart failure, left ventricular dysfunction (ejection fraction <0.40), hypertension, or diabetes. IA: Lipid-lowering agents and diet in post-acute coronary syndromes patients including patients who are post revascularization with low-density lipoprotein cholesterol of >125 mg/dl, including after revascularization. A fibrate or niacin if high-density lipoprotein cholesterol is <40 mg/dl, occurring as an isolated finding or in combination with other lipid abnormalities. IB: Clopidogrel 75 mg/day in patients with a contraindication to aspirin. IB: Beta-blockers in the absence of contraindications.